Immune effector cell (IEC) therapies, commonly referred as cell therapies, utilize human cells to cause or enhance an immune response against tumor cells. Following remarkable successes with several patients in the early 2010s – most notably, the case of Emily Whitehead, the first pediatric CAR-T patient, who recently celebrated 10 years of being cancer-free – IECs have become a key focus of investigations to help treat multiple types of cancer
Our CEO Erik Nordhoy talks about the new partnership SAI MedPartners has recently taken on a strategic investment from Northlane Capital Partners, a leading private equity firm focused on the healthcare sector. This investment will provide growth capital to enable SAI to accelerate key initiatives to strengthen our client engagement model, augment our suite of […]